Zacks Investment Research upgraded shares of Fluidigm Corp. (NASDAQ:FLDM) from a sell rating to a hold rating in a report issued on Wednesday morning.

According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “

Other analysts also recently issued reports about the stock. Cantor Fitzgerald reissued a buy rating and issued a $13.00 price target on shares of Fluidigm Corp. in a report on Thursday, June 2nd. Deutsche Bank AG began coverage on shares of Fluidigm Corp. in a report on Wednesday, June 1st. They issued a buy rating for the company. Finally, Mizuho increased their price target on shares of Fluidigm Corp. from $11.00 to $12.00 and gave the company a buy rating in a report on Friday, August 5th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Fluidigm Corp. presently has a consensus rating of Buy and an average price target of $13.67.

Shares of Fluidigm Corp. (NASDAQ:FLDM) opened at 8.13 on Wednesday. Fluidigm Corp. has a 52 week low of $4.84 and a 52 week high of $12.09. The firm’s market capitalization is $236.06 million. The stock has a 50 day moving average of $9.03 and a 200-day moving average of $9.11.

Fluidigm Corp. (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.06. Fluidigm Corp. had a negative net margin of 52.04% and a negative return on equity of 45.68%. The company earned $28.20 million during the quarter, compared to the consensus estimate of $29.62 million. During the same period last year, the company earned ($0.53) earnings per share. Fluidigm Corp.’s revenue for the quarter was down 1.5% on a year-over-year basis. Analysts expect that Fluidigm Corp. will post ($2.32) earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. Cookson Peirce & Co. Inc. purchased a new stake in shares of Fluidigm Corp. during the second quarter worth about $123,000. BlackRock Advisors LLC boosted its stake in shares of Fluidigm Corp. by 10.4% in the second quarter. BlackRock Advisors LLC now owns 14,529 shares of the company’s stock worth $131,000 after buying an additional 1,373 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Fluidigm Corp. by 89.3% in the second quarter. Parametric Portfolio Associates LLC now owns 21,070 shares of the company’s stock worth $190,000 after buying an additional 9,939 shares during the period. Stoneridge Investment Partners LLC purchased a new stake in shares of Fluidigm Corp. during the second quarter worth about $220,000. Finally, AQR Capital Management LLC boosted its stake in shares of Fluidigm Corp. by 58.8% in the second quarter. AQR Capital Management LLC now owns 25,187 shares of the company’s stock worth $227,000 after buying an additional 9,324 shares during the period. Institutional investors and hedge funds own 93.33% of the company’s stock.

Fluidigm Corp. Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

5 Day Chart for NASDAQ:FLDM

Get a free copy of the Zacks research report on Fluidigm Corp. (FLDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fluidigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corp. and related companies with MarketBeat.com's FREE daily email newsletter.